These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 16258760)
1. Immunoglobulin KM allotypes are associated with the prevalence of autoantibodies to GD1a ganglioside, but not with susceptibility to the disease, in Japanese patients with Guillain-Barré syndrome. Pandey JP; Koga M; Yuki N Neurogenetics; 2005 Dec; 6(4):225-8. PubMed ID: 16258760 [TBL] [Abstract][Full Text] [Related]
2. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ogawara K; Kuwabara S; Mori M; Hattori T; Koga M; Yuki N Ann Neurol; 2000 Oct; 48(4):624-31. PubMed ID: 11026446 [TBL] [Abstract][Full Text] [Related]
3. Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GalNAc-GD1a antibodies. Ang CW; Yuki N; Jacobs BC; Koga M; Van Doorn PA; Schmitz PI; Van Der Meché FG Neurology; 1999 Dec; 53(9):2122-7. PubMed ID: 10599792 [TBL] [Abstract][Full Text] [Related]
5. Guillain Barré Syndrome is induced in Non-Obese Diabetic (NOD) mice following Campylobacter jejuni infection and is exacerbated by antibiotics. St Charles JL; Bell JA; Gadsden BJ; Malik A; Cooke H; Van de Grift LK; Kim HY; Smith EJ; Mansfield LS J Autoimmun; 2017 Feb; 77():11-38. PubMed ID: 27939129 [TBL] [Abstract][Full Text] [Related]
6. Spectrum of neurological diseases associated with antibodies to minor gangliosides GM1b and GalNAc-GD1a. Tatsumoto M; Koga M; Gilbert M; Odaka M; Hirata K; Kuwabara S; Yuki N J Neuroimmunol; 2006 Aug; 177(1-2):201-8. PubMed ID: 16844234 [TBL] [Abstract][Full Text] [Related]
7. Campylobacter coli enteritis and Guillain-Barré syndrome: no evidence of molecular mimicry and serological relationship. Funakoshi K; Koga M; Takahashi M; Hirata K; Yuki N J Neurol Sci; 2006 Jul; 246(1-2):163-8. PubMed ID: 16600306 [TBL] [Abstract][Full Text] [Related]
8. The immunobiology of Guillain-Barré syndromes. Willison HJ J Peripher Nerv Syst; 2005 Jun; 10(2):94-112. PubMed ID: 15958123 [TBL] [Abstract][Full Text] [Related]
9. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome. Koga M; Takahashi M; Masuda M; Hirata K; Yuki N Neurology; 2005 Nov; 65(9):1376-81. PubMed ID: 16162859 [TBL] [Abstract][Full Text] [Related]
10. Prospective study on anti-ganglioside antibodies in childhood Guillain-Barré syndrome. Schessl J; Koga M; Funakoshi K; Kirschner J; Muellges W; Weishaupt A; Gold R; Korinthenberg R Arch Dis Child; 2007 Jan; 92(1):48-52. PubMed ID: 16920757 [TBL] [Abstract][Full Text] [Related]
11. Guillain-Barré syndrome with antibody to a ganglioside, N-acetylgalactosaminyl GD1a. Kaida K; Kusunoki S; Kamakura K; Motoyoshi K; Kanazawa I Brain; 2000 Jan; 123 ( Pt 1)():116-24. PubMed ID: 10611126 [TBL] [Abstract][Full Text] [Related]
12. Anti-ganglioside antibodies in patients with Guillain Barré syndrome and other neurological disorders. Vaishnavi C; Behura C; Prabhakar S; Sharma A; Kharbanda P Indian J Med Microbiol; 2013; 31(2):177-9. PubMed ID: 23867676 [TBL] [Abstract][Full Text] [Related]
13. Anti-ganglioside complex antibodies associated with severe disability in GBS. Kaida K; Morita D; Kanzaki M; Kamakura K; Motoyoshi K; Hirakawa M; Kusunoki S J Neuroimmunol; 2007 Jan; 182(1-2):212-8. PubMed ID: 17113161 [TBL] [Abstract][Full Text] [Related]
14. Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a. Mauri L; Casellato R; Ciampa MG; Uekusa Y; Kato K; Kaida K; Motoyama M; Kusunoki S; Sonnino S Glycobiology; 2012 Mar; 22(3):352-60. PubMed ID: 21921061 [TBL] [Abstract][Full Text] [Related]
15. Guillain-Barré syndrome with IgM antibody to the ganglioside GalNAc-GD1a. Kaida K; Kusunoki S; Kamakura K; Motoyoshi K; Kanazawa I J Neuroimmunol; 2001 Feb; 113(2):260-7. PubMed ID: 11164910 [TBL] [Abstract][Full Text] [Related]
16. Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barré syndrome and its variants. Koga M; Takahashi M; Yokoyama K; Kanda T J Neurol; 2015 Aug; 262(8):1954-60. PubMed ID: 26050638 [TBL] [Abstract][Full Text] [Related]
17. Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review. Kaida K; Ariga T; Yu RK Glycobiology; 2009 Jul; 19(7):676-92. PubMed ID: 19240270 [TBL] [Abstract][Full Text] [Related]
18. GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barre syndrome. Kaida K; Sonoo M; Ogawa G; Kamakura K; Ueda-Sada M; Arita M; Motoyoshi K; Kusunoki S Neurology; 2008 Nov; 71(21):1683-90. PubMed ID: 19015484 [TBL] [Abstract][Full Text] [Related]
19. [A case of Guillain-Barré syndrome after Campylobacter jejuni enterocolitis: anti-ganglioside antibody levels with or without Guillain-Barré syndrome]. Watanabe H; Shindo K; Nakamura Y; Nagamatsu M; Shiozawa Z; Kusunoki S Rinsho Shinkeigaku; 2001 Sep; 41(9):625-7. PubMed ID: 11968750 [TBL] [Abstract][Full Text] [Related]
20. Antibodies against ganglioside complexes in Guillain-Barré syndrome and related disorders. Kusunoki S; Kaida K J Neurochem; 2011 Mar; 116(5):828-32. PubMed ID: 21214559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]